Reddy S V, Maderdrut J L, Yaksh T L
J Pharmacol Exp Ther. 1980 Jun;213(3):525-33.
Intrathecal administration of norepinephrine (NE) and alpha adrenergic agonists in rats with chronic spinal catheters produced a significant elevation of the nociceptive threshold as measured by hot plate and tail flick. The intrathecal NE effect was dose-dependent and antagonized in a competitive fashion by pretreatment with phentolamine (alpha antagonist) but not by propranolol (beta antagonist). Intrathecal administration of isoproterenol (beta agonist) did not alter the nociceptive threshold. Effective doses of intrathecal NE did not produce demonstrable motor effects. Doses 20 times greater than the maximum analgesic dose produced marked weakness of the hindlimbs and tails. The intrathecal NE effect was not antagonized by intrathecal papaverine of bradykinin (vasodilators) or mimicked by angiotensin-II (vasoconstrictor). The intrathecal NE effect was not altered by intrathecal administration of subconvulsant doses of either picrotoxin (gamma-aminobutyric acid antagonist) or strychnine (glycine antagonist) or by i.p. administration of either naloxone (opiate antagonist) or methysergide (serotinin antagonist). The nociceptive threshold was significantly decreased 1 week after intrathecal administration of 6-hydroxydopamine, which depleted spinal cord NE by 85%. Intrathecal administration of tyramine (indirectly acting sympathomimetic amine) produced an elevation of the nociceptive threshold in a control group of animals but was less effective in animals pretreated with intrathecal 6-hydroxydopamine. The tyramine effect was antagonized by intrathecal phentolamine. Intravenous administration of aminophylline (phosphodiesterase inhibitor) did not potentiate the intrathecal NE effect. The relative antinociceptive potencies of alpha adrenergic agonists after intrathecal administration were: l-norepinephrine = dl-epinephrine greater than dl-alpha-methyl norepinephrine greater than clonidine greater than or equal to l-phenylephrine greater than or equal to 3,4-dihydroxytolazoline greater than or equal to oxymetazoline. The relative potencies of intrathecally administered alpha antagonists in antagonizing the intrathecal NE effect were: phentolamine greater than phenoxybenzamine greater than tolazoline greater than or equal to yohimbine.
对植入慢性脊髓导管的大鼠鞘内注射去甲肾上腺素(NE)和α肾上腺素能激动剂,通过热板法和甩尾法测量发现,伤害性感受阈值显著升高。鞘内注射NE的效应呈剂量依赖性,预先用酚妥拉明(α拮抗剂)预处理可竞争性拮抗该效应,而普萘洛尔(β拮抗剂)则不能。鞘内注射异丙肾上腺素(β激动剂)不会改变伤害性感受阈值。有效剂量的鞘内NE不会产生明显的运动效应。比最大镇痛剂量大20倍的剂量会导致后肢和尾巴明显无力。鞘内注射罂粟碱或缓激肽(血管扩张剂)不会拮抗鞘内NE的效应,血管紧张素-II(血管收缩剂)也不会模拟该效应。鞘内注射亚惊厥剂量的印防己毒素(γ-氨基丁酸拮抗剂)或士的宁(甘氨酸拮抗剂),或腹腔注射纳洛酮(阿片类拮抗剂)或甲基麦角新碱(5-羟色胺拮抗剂),均不会改变鞘内NE的效应。鞘内注射6-羟基多巴胺1周后,伤害性感受阈值显著降低,脊髓NE减少了85%。鞘内注射酪胺(间接作用的拟交感神经胺)可使对照组动物的伤害性感受阈值升高,但在预先鞘内注射6-羟基多巴胺的动物中效果较差。酪胺的效应可被鞘内注射酚妥拉明拮抗。静脉注射氨茶碱(磷酸二酯酶抑制剂)不会增强鞘内NE的效应。鞘内注射后α肾上腺素能激动剂的相对抗伤害感受效力为:左旋去甲肾上腺素=消旋肾上腺素>消旋α-甲基去甲肾上腺素>可乐定≥左旋苯肾上腺素≥3,4-二羟基妥拉唑啉≥羟甲唑啉。鞘内注射α拮抗剂拮抗鞘内NE效应的相对效力为:酚妥拉明>酚苄明>妥拉唑啉≥育亨宾。